Genflow Biosciences Plc · LSE:GENF
Genflow Biosciences — Investor Presentation (March 2024)
18 slides from Genflow Biosciences's investor presentation, March 2024
Slide 1: Corporate Overview March 2024
CORPORATE OVERVIEW March 2024 gb LSE: GENF - OTCQB: GENFF
Slide 2: Forward Looking Statements
FORWARD LOOKING STATEMENTS This presentation contains express or implied information and statements that might be deemed forward-looking information and statements in respect of Genflow Biosciences. They do not constitute historical facts. Certain information and statements include financial project
Slide 3: Who We Are
WHO WE ARE Pioneering Novel Gene Therapeutics for a Longer, Healthier Life MISSION: aging is underlying risk factor for disease, and our aim is to deliver gene therapeutics that potentially halt or slow the aging process in humans and dogs PROMISING PRECLINICAL RESULTS: lead drug candidate GF-1002 d
Slide 4: Aging Is One of Our Greatest Societal & Economical Challenges
MARKET Aging Is One of Our Greatest Societal & Economical Challenges Increasing life expectancy, decreasing healthspan, rising healthcare costs – all highlight the urgent need for age-related disease treatments 12-13 yrs* *expected LE in relation to male babies born in the UK in 2018 Source: Morgan
Slide 5: Gene Regulation in Aging (SIRT6)
GENE REGULATION IN AGING Aging is a function of overworked epigenetic regulator genes unable to respond to cellular DNA damage GENOME INSTABILITY MANY GENES REGULATE AGING. ALTERED INTRA CELLULAR TELOMERE OUR FOCUS IS THE SIRT6 GENE ATTRITION COMMUNICATION Aging is driven by 9 interlinked Hallmarks,
Slide 6: SIRT6: Repairing DNA
SIRT6: REPAIRING DNA SIRT6 gene/protein repairs DNA damage (especially double strand breaks (DSB)) and prevents senescence of our cells SIRT6 gene codes for SIRT6 protein Stronger SIRT6: Longer lifespan The Ability of SIRT6 to stimulate DSB repair corelates with maximum lifespan (MLS) in rodents EP
Slide 7: Focus on Centenarian SIRT6
FOCUS ON CENTENARIAN SIRT6 SIRT6 centenarian variant gene has more efficient DNA repair properties HOMOLOGOUS NON-HOMOLOGOUS RELATIVE PARP1 Recombination Repair End Joining Repair Ribosilation LSE: GENF - OTCQB: GENFF 7
Slide 8: Development Pipeline
DEVELOPMENT PIPELINE UNIVERSITY GF-1002 (Pre-Clinical) –Exo-AAV vector for Phase I/II NASH OF ROCHESTER intravenous infusion, expressing cDNA of PoC in 36 patients UNIVERSITY OF LIVERPOOL centenarian variant of SIRT6 in liver IND-Enabling Phase 18 months to first-in- COLLABORATIONS human UNIVERSITY
Slide 9: NASH Program
NASH PROGRAM Affects est. 35 million people globally • Increasing prevalence • Leading cause of chronic liver disease and liver transplant Significant unmet medical need Clear regulatory accelerated development pathway. EMA and FDA guidelines accept: ✓ Key surrogate outcomes for therapeutic trials:
Slide 10: Exosome Delivery System: Safe and Cost-Effective
EXOSOME DELIVERY SYSTEM: SAFE AND COST-EFFECTIVE Genflow’s patent-pending technology has already been tested in several preclinical studies Non- Integrating, Non- No Risk Replicating, of Insertional Safe Transient Oncogenesis Expression Reduced Potential for Immunogenicity LSE: GENF - OTCQB: GENFF 1
Slide 11: Advantages: Exosome Delivery
ADVANATGES: EXOSOME DELIVERY Exo-AAV can mediate efficient, specific, and more durable SIRT6 expression in liver compared to conventional AAV POTENCY ADVANTAGE NO IMMUNOGENICITY Improved Transduction Lack of Local Systemic Verses Free AAVs Rapid Uptake Immunogenicity Sustained TARGETED THERAPEUTIC D
Slide 12: 2023 Key Highlights & 2024 Priorities
2023 KEY HIGHLIGHTS & 2024 PRIORITIES GROWING IP PORTFOLIO Provisional patent application in 2023 for editing SIRT6 gene, linked to longevity and age-related diseases EXPANDED MARKET SIRTUIN 6 GENE Awarded to new grants in 2023 & 2024 expanding research pipeline and (SIRT6) size of therapeutic marke
Slide 13: 2023 Key Highlights & 2024 Priorities
2023 KEY HIGHLIGHTS & 2024 PRIORITIES LARGE MARKET OPPORTUNITY NASH: 35 Million globally. Increasing prevalence. Door opener to even broader anti-aging indication LONG LIFE IP SIRTUIN 6 GENE 2 patent families SIRT6 centenarian and gene delivery (entering (SIRT6) National Phase); Additional upcoming
Slide 14: Management
MANAGEMENT TAMARA JOSEPH DR ERIC LEIRE MD MBA Chairperson Founder & CEO • Seasoned healthcare leader with extensive experience • MD and MBA, Eric has been involved in in both early-stage and commercial biotech companies biotech for over 30 years • Supported Nasdaq financings of over $800m • Held sen
Slide 15: Scientific Advisory Board
SCIENTIFIC ADVISORY BOARD DR. ERIC VERDIN DR. VERA DR. MATTHEW DR. MANLIO PROF. DR. SVEN DR. MARY MD/PHD GORBUNOVA, PHD HIRSCHEY, PHD VINCIGUERRA, PHD FRANCQUE, PHD RINELLA, MD CEO & President CO Director Assistant Professor Principle Investigator NASH Expert NASH Expert Buck Institute Rochester Agi
Slide 16: Thank You
THANK YOU Contact CEO, GENFLOW BIOSCIENCES Dr. Eric Leire: +32 477 495 881 HARBOR ACCESS INVESTOR RELATIONS Jonathan Paterson : +1 475 477 9401 GENFLOW BIOSCIENCES SRL Biopark Gosselies 48 rue Auguste Piccard 6041 Gosselies, Belgium GENFLOW BIOSCIENCES INC. Harvard Square 18 Brattle Street, Suite 40
Slide 17: Intellectual Property
INTELLECTUAL PROPERTY EFS ID 1-21069 43268050 Application Number US 63/188,573 US 63/222,557 Method of in vivo administration of the Variants of SIRT6 for use in preventing and/or treating coding sequence of the SIRT6 gene Title of Invention age-related diseases via Adeno-Associated-Virus First Name
Slide 18: Longevity Landscape
LONGEVITY LANDSCAPE COMPANY OVERVIEW TECHNOLOGY FOCUSED ON LOCATION CLINICAL STAGE, PHASE II Small Molecules Senescence USA, San Francisco, CA NASDAQ (UBX) MKT CAP $785M Senolytic PRE-CLINICAL STAGE Therapeutics that seek to Stem cells USA, Almeda, CA NYSE (AGE) MKT CAP $25M address human aging CLIN
Genflow Biosciences — Investor Presentation (March 2024) on 6ix